Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Galmed Pharmaceuticals Ltd    GLMD   IL0011313900

GALMED PHARMACEUTICALS LTD (GLMD)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/14/2018 09/17/2018 09/18/2018 09/19/2018 09/20/2018 Date
13(c) 12.85(c) 12.61(c) 12.79(c) 12.83(c) Last
69 898 89 228 232 968 167 024 109 643 Volume
-0.23% -1.15% -1.87% +1.43% +0.31% Change
More quotes
Financials (USD)
Sales 2018 0,82 M
EBIT 2018 -10,2 M
Net income 2018 -11,1 M
Debt 2018 -
Yield 2018 -
Sales 2019 0,53 M
EBIT 2019 -24,3 M
Net income 2019 -22,9 M
Finance 2019 50,0 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 326x
EV / Sales2019 411x
Capitalization 267 M
More Financials
Company
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company.It focuses on the development of the liver targeted stearoyl-coenzyme A desaturase-1 modulator Aramchol, novel, once-daily, oral therapy for the treatment of NASH for variable populations, as well as other liver associated... 
More about the company
Surperformance© ratings of Galmed Pharmaceuticals Ltd
Trading Rating : Investor Rating :
More Ratings
Latest news on GALMED PHARMACEUTICALS LTD
07/13TODAY'S RESEARCH REPORTS ON STOCKS T : Galmed Pharmaceuticals and Zogenix
AC
06/13GALMED PHARMACEUTICALS LTD : Comprehensive Research Report, Galmed Pharmaceutica..
AC
04/16GALMED PHARMACEUTICALS : to Host Post-EASL Key Opinion Leader Call on the Scient..
PU
03/13GALMED PHARMACEUTICALS LTD : Galmed Pharmaceuticals Ltd. to Host Earnings Call
AC
2017GALMED PHARMACEUTICALS : Reports Third Quarter 2017 Financial Results and Provid..
PU
2017GALMED PHARMACEUTICALS LTD : Galmed Pharmaceuticals Ltd. to Host Earnings Call
AC
2017GALMED PHARMACEUTICALS : Announces Publication of Data on Aramchol™ Mechan..
PU
2017GALMED PHARMACEUTICALS : to Present at International Liver Congress Data that Sh..
PU
2016GALMED PHARMACEUTICALS : and the University of California, San Diego Enter into ..
PU
2016GALMED PHARMACEUTICALS : and SAMIL Pharm Sign a License Agreement for the Commer..
PU
More news
Sector news : Bio Therapeutic Drugs
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug in First European Setback -..
DJ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug for Some Patients Despite D..
DJ
09/19GILEAD SCIENCES : UK rejects adult Novartis CAR-T therapy, after 'yes' in kids
RE
09/18REGENERON PHARMACEUTICALS : Sanofi pledges to keep up its restructuring efforts
RE
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans
DJ
More sector news : Bio Therapeutic Drugs
Latest Tweets
09/17sWings of interest on the long side IF AND ONLY IF they can get thru their pr.. 
09/17Galmed Pharmaceuticals Ltd $GLMD Sees Large Drop in Short Interest  
09/07BIOLINERX Ltd/S $BLRX versus Galmed Pharmaceuticals $GLMD Head to Head Contra.. 
09/05Get the latest ratings for $GLMD $ZAVVV $PUMP $LGF.A $BOJA in your inbox with.. 
09/03Zacks: Analysts Expect Galmed Pharmaceuticals Ltd $GLMD Will Post Earnings of.. 
More tweets
Qtime:17
News from SeekingAlpha
09/10Breaking Down The NASH Fibrosis Market - Intercept, Genfit Primed For Potenti.. 
08/28NASH CIRRHOSIS : The Real NASH Epidemic 
08/27GALMED PHARMACEUTICALS : Buy This NASH Play? 
08/04Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2018 Results - Ea.. 
08/02Galmed misses by $0.01, revenue in-line 
Chart GALMED PHARMACEUTICALS LTD
Duration : Period :
Galmed Pharmaceuticals Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GALMED PHARMACEUTICALS LTD
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 34,6 $
Spread / Average Target 171%
EPS Revisions
Managers
NameTitle
Allen Baharaff President, Chief Executive Officer & Director
Chaim Hurvitz Chairman
Guy Nehemya Vice President-Operations
Yohai Stenzler Chief Financial Officer
Liat Hayardeny Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GALMED PHARMACEUTICALS LTD40.22%267
GILEAD SCIENCES3.13%95 774
VERTEX PHARMACEUTICALS18.19%45 132
REGENERON PHARMACEUTICALS3.29%40 728
NEUROCRINE BIOSCIENCES, INC.54.99%10 622
SAREPTA THERAPEUTICS INC173.09%10 096